Spectral AI, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ryan Zimmerman from BTIG maintained a Buy rating on the stock and has a $3.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ryan Zimmerman has given his Buy rating due to a combination of factors, despite some short-term setbacks. The company reported lower-than-expected revenue and earnings for the third quarter of 2025, primarily due to the timing of work on a government contract and the impact of a government shutdown. However, these issues are expected to be mitigated in the following fiscal year, with significant revenue anticipated upon FDA clearance of their DeepView system.
Additionally, Spectral AI is on track with key milestones, including the submission of regulatory filings to the FDA and the planned spin-off of its IP subsidiary. The company is also progressing with the development of a miniaturized version of its DeepView system, aimed at military and commercial applications. Despite the current financial challenges, the long-term growth prospects, particularly with the commercial launch of DeepView, support the Buy rating, as revenue is expected to grow significantly in the coming years.